Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06816355 · ClinicalTrials.gov registry record
Exogenous Sex Hormones and PONV
A clinical trial, sponsored by Riverside University Health System Medical Center.
- Completed
- Registry status
- 7,348
- Enrollment target
NCT06816355 is a clinical trial that has completed, run by Riverside University Health System Medical Center. The registered enrollment target is 7,348 participants.
The verdict
NCT06816355 has completed, sponsored by Riverside University Health System Medical Center.
- COMPLETED
- Registry status
- 7,348 participants
- Enrollment target
Study Summary
This study aims to investigate the rates of postoperative nausea and vomiting in transgender patients on hormone therapy compared to cisgender patients undergoing the same procedures (hysterectomy, orchiectomy, augmentation mammoplasty).
Interventions
- PROCEDURE Hysterectomy
- PROCEDURE Orchiectomy
- PROCEDURE Augmentation mammoplasty
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7,348 participants |
| Start Date | 2025-02-04 |
| Est. Completion | 2025-02-04 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06816355
The ClinicalTrials.gov registry entry for NCT06816355 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 7,348 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Riverside University Health System Medical Center, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Hysterectomy is the first listed.
NCT06816355 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06816355 about?
NCT06816355 is a clinical study titled "Exogenous Sex Hormones and PONV". This study aims to investigate the rates of postoperative nausea and vomiting in transgender patients on hormone therapy compared to cisgender patients undergoing the same procedures (hysterectomy, orchiectomy, augmentation mammoplasty).
What is the current status of trial NCT06816355?
This trial is currently completed. The enrollment target is 7,348 participants. The study started on 2025-02-04. Estimated completion is 2025-02-04.
What interventions are being tested in trial NCT06816355?
The interventions under investigation include: Hysterectomy (PROCEDURE), Orchiectomy (PROCEDURE), Augmentation mammoplasty (PROCEDURE).
Who is sponsoring clinical trial NCT06816355?
This trial is sponsored by Riverside University Health System Medical Center, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.